CIRP GAPDH
A549 Mock control
NS control siRNA 214
siRNA 292 siRNA 558
A .
CIRP GAPDH
H460 CIRP
GAPDH
A549 Mock control
NS control
siRNA 214/292
B .
CIRP GAPDH
H1299 Control
Le-control
Le-CIRP
C .
CIRP GAPDH
H1650
H460
G1/G0: 43.28%
S: 39.48%
G2/M: 13.17%
G1/G0: 50.91%
S: 31.13%
G2/M: 13.34%
G1/G0: 34.42%
S: 47.07%
G2/M: 15.52%
A549
G1/G0: 47.67%
S: 36.42%
G2/M: 11.39%
H1650
G1/G0: 51.80%
S: 26.77%
G2/M: 21.43%
G1/G0: 35.71%
S: 41.81%
G2/M: 22.48%
G1/G0: 57.03%
S: 28.04%
G2/M: 14.93%
H1299
G1/G0: 41.16%
S: 41.39%
G2/M: 17.45%
Le-CIRP Le-control
B.
GAPDH CIRP
1 MOl
A549
10 MOl 1 MOl 10 MOl
Le- shCIRP D.
Le-scrambled
Control
GAPDH CIRP
1 MOl
H460
10 MOl 1 MOl 10 MOl
Le- shCIRP E.
Le-scrambled
Control
Le-control
A549 H460
Le-CIRP
A549 0
100 200 300 400 500 600
Cell numbers
**
H460 0
100 200 300 400 500
600 Le-control
Le-CIRP
Cell numbers
**
B. A549 H460
Le-controlLe-CIRP
C.
A549 0
40 80 120 160 200 240
Cell numbers
*
H460 0
40 80 120 160 200
240 Le-con-
trolLe-CIRP
Cell numbers
**
CIRP
GAPDH
A549 Control
Le-control
Le-CIRP
A .
H460 Control
Le-control
Le-CIRP
Le-scrambled (n = 10) Le-shCIRP (n = 10) A.
B.
Le-scrambled Le-shCIRP
H&ECIRP
C.
A.
Le-control Le-CIRP Le-control Le-CIRP
A549 H460
GAPDH CTNNB1 C-myc COX-2
VEGFA CCND1
CD44 MMP7 CIRP
C .
CTNNB1 CIRP
C-myc COX-2 CCND1
MMP7 VEGFA
CD44 GAPDH
A549 Le- control
Le- CTNNB1
B .
siRNA 214/292 － + － +
NS control + － + －
45.30%
36.10%
18.60%
Tumor
Strong staining Moderate stain- ing
Weak staining
B .
22.10%
62.80%
15.10%
Noncancerous lung tissue
Strong staining Moderate staining Weak staining
C .
Strong
staining
Moderatestaining Weak stainingTumorNoncancerous tissue
D .
Le-scrambled Le-shCTNNB1
H&ECTNNB1
C .
B .
Le-scrambled (n = 9)
Le-shCTNNB1 (n = 9)
A .
CTNNB1 site1F CAGGAAGGGATGGAAGGTCTC CTNNB1 site1R TCACGCAAAGGTGCATGATTT CTNNB1 site2F AGACGGAGGAAGGTCTGAGG CTNNB1 site2R GGCCATGTCCAACTCCATCA 100bp
250bp 500bp 1000bp 1500bp 2000bp
Input IgG CIRP Input IgG CIRP
CTNNB1 site2 CTNNB1 site1
.
B
.
CMVpromoter FLBGH poly A
SV40
promoter RL
SV40 poly A
pC3.1/CDS report CTNNB1 CDS
2346 bp
IgG CIRP
0%
20%
40%
60%
80%
100%
120%
pC3.1/CDS report
Relative firefly luciferase mRNA (normalized to input)
C. D.
0 10 20 30
0%
20%
40%
60%
80%
100%
pC3.1/CDS report
Linear ()
Actinomycin D (min)
Relative firefly luciferase mRNA
E.
0 0.2 0.4 0.6 0.8 1
1.2 NS contr ol
siRNA 21 4/29 2
Relative luciferase activity(FL/RL)
